FOMAT is strengthening its clinical trial site management California operations through a strategic restructuring of its Clinical Operations department. This transformation is designed to enhance scalability, improve quality standards, and reinforce FOMAT’s commitment to patient safety across its network of 26 investigator sites statewide. For sponsors and CROs evaluating site partners in California, this restructuring signals a maturing organization built for long term growth and operational excellence.<\/p>\n
As demand for clinical research services continues to grow across therapeutic areas, FOMAT has responded with a proactive operational overhaul that positions the organization to support more complex and higher volume trial portfolios without compromising quality or efficiency. This investment in infrastructure reflects a broader commitment to building the systems and leadership required to sustain rapid expansion while maintaining the high standards that sponsors and CROs expect from a trusted research partner.<\/p>\n
Building Infrastructure to Match Expansion<\/strong><\/em><\/p>\n FOMAT’s Clinical Operations restructuring creates a scalable model that supports the company’s rapid expansion across California. The new structure ensures that FOMAT can continue to meet the evolving needs of sponsors, CROs, and patients as the site network grows. By investing in the right operational framework now, FOMAT is building the capacity to take on more trials, more therapeutic areas, and more complex protocols without sacrificing the quality that defines its reputation.<\/p>\n “Our focus on professionalization is a critical aspect of our expansion strategy,” stated Nicholas Focil, CEO of FOMAT. “By restructuring Clinical Operations, we are ensuring that our model is built to scale efficiently while maintaining our dedication to quality and patient care.”<\/p>\n Leadership Driving the Transformation<\/strong><\/em><\/p>\n A cornerstone of this restructuring is the appointment of Dr. Susana Moyano as Clinical Operations Director. Her background as an MD and former leader of FOMAT’s Quality Management department makes her uniquely positioned to guide this transformation. Dr. Moyano’s dual expertise in medicine and quality management enables her to bridge clinical and operational priorities, ensuring that patient safety remains central to every process improvement.<\/p>\n Her appointment reflects FOMAT’s philosophy that strong clinical trial site management California wide requires leadership that understands both the science of clinical research and the operational demands of running a high performing site network. Dr. Moyano brings exactly that combination, and her experience leading quality management positions her to drive continuous improvement across all 26 FOMAT sites.<\/p>\n Quality and Patient Safety as Core Priorities<\/strong><\/p>\n Professionalizing Clinical Operations<\/strong><\/em><\/p>\n This restructuring reflects FOMAT’s commitment to delivering excellence in clinical trial site management California wide. By optimizing internal processes and prioritizing professionalization, FOMAT is reinforcing its role as a trusted partner for sponsors and CROs seeking consistent, high quality site performance. The new operational framework is designed to adapt to future demands, ensuring that FOMAT remains at the forefront of clinical research innovation across all therapeutic areas.<\/p>\n Every process improvement introduced through this restructuring is evaluated against two core criteria: does it enhance patient safety, and does it improve the experience and efficiency of the sponsors and CROs who partner with FOMAT? This dual focus ensures that operational changes translate into measurable improvements in trial quality and site performance.<\/p>\n What This Means for Sponsors and CROs<\/strong><\/em><\/p>\n For industry partners, FOMAT’s restructured Clinical Operations department translates into faster site activation, stronger protocol adherence, and more consistent data quality across all 26 California sites. Sponsors and CROs can expect a partner that has invested in the systems and leadership required to support large scale, multi site trial execution with the rigor demanded by Phase I through IV research.<\/p>\n